According to the report, treatment with PCSK9 inhibitors generates cost-effectiveness ratios that exceed the commonly-accepted $100,000 per quality-adjusted life year (QALY).

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing ...

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...

The potential for targeting PCSK9 in people with uncontrollably high cholesterol has not yet been fully realized. When Amgen’s PCSK9 inhibitor Repatha and the rival Sanofi/Regeneron drug ...

The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across ...

Between PCSK9 inhibitor and the time of the analysis, median total cholesterol fell from 210 mg/dL to 133 mg/dL, median LDL fell from 125 mg/dL to 53 mg/dL, median non-HDL fell from 158 mg/dL to ...

MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...

Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing Peer-Reviewed Publication Science China Press ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel target for low-density lipoprotein cholesterol (LDL-C)-lowering therapy, has been found to possess multiple off-target effects in ...

PCSK9 was discovered in 2003. In 2003, researchers in France discovered PCSK9 while examining families with extremely high cholesterol and early heart attacks, according to the American Heart ...

PCSK9 Inhibitor Prices Should Fall Two-Thirds for Cost-effectiveness: Analysis Larry Hand August 16, 2016 0 ...